ClinicalTrials.gg
Active, not recruitingNCT03963349STSFUpdated Nov 3, 2026

THERMOCOOL SMARTTOUCH®SF Catheters With Ablation Index Study

An observational study in Paroxysmal Atrial Fibrillation, sponsored by Biosense Webster, Inc.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Biosense Webster, Inc. (part of Johnson & Johnson) · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
150
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Atrial Fibrillation by Johnson & Johnson — 7 open to participants now, 12 under way, 1 of them phase 3. Atrial Fibrillation · Johnson & Johnson.

Planned enrollment
12th of 13
150 · median 426
Started
2019
with 1 other
Observational
13 of 71
1 open now
Primary completion
2026-12
later than 0 of 11 live
Registered
45th of 71
by date

Among the 71 studies in Atrial Fibrillation by Johnson & Johnson, this one is the 12th largest by planned enrollment of the 13 observational ones that give a count, is one of 2 that started in 2019, is one of 13 observational ones, reaches primary completion later than 0 of the 11 other live ones, and was the 45th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

7 of the 71 studies in Atrial Fibrillation by Johnson & Johnson are open now, in 5 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 71 studies in Atrial Fibrillation by Johnson & Johnson, or all of them as a file.
02

Study summary

A single-center, real word study of consecutive subjects who undergo radiofrequency ablation for paroxysmal AF using THERMOCOOL SMARTTOUCH®SF (STSF) Catheter guiding by Ablation Index (AI). Prospectively or retrospectively record 150 eligible subjects since 1st Jan 2019 to evaluate effectiveness and safety of STSF with AI.

Read the detailed description

The purpose of this study is to measure the long term effectiveness,clinical benefit, and safety outcomes of catheter ablation with STSF and AI for paroxysmal atrial fibrillation (PAF) subjects up to 12-month follow-up.

Subject:Up to 150 PAF subjects will be included in the study data, representing all consecutive subjects having catheter ablation with AI guiding STSF and for the treatment of PAF at the site.

Primary endpoint: The primary endpoint is freedom from documented atrial fibrillation (AF), atrial tachycardia (AT), or atrial flutter (AFL) (≥30 seconds) within 91-365 days post index procedure.

Secondary endpoint : Acute success at 0.5hour CPVI (i.e. entrance block achieved in all veins, verified via an isoproterenol intravenous challenge)

  • Numbers of reconnected pulmonary veins (PV), with number and location of any gaps
  • Procedural efficiency measures(e.g. mapping time, ablation time, total procedure time, and fluid volume delivered via catheter.
  • AI values
  • Inter-Tag distances
  • Adverse events (Complications related to device or procedure)
  • Re-hospitalization due to arrhythmia recurrence or procedure-related reasons up to 1 year Clinical Study Sites: Shanghai General Hospital Study Duration: 18-month enrollment period, with follow-up at 3, 6 and 12 months after ablation, with a blanking period defined as the period within 90 days after the ablation.
03

Conditions studied

  • Paroxysmal Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

PAF population patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older
  2. Patient has PAF eligible for AI-guided catheter ablation with an STSF catheter per standard of care assessment
  3. Able and willing to comply with all pre-, post- and follow-up testing and requirements
  4. Able to sign EC-approved form

Exclusion criteria

Exclusion Criteria:

  1. AF is secondary to electrolyte imbalance, thyroid disease, or a reversible or non-cardiac cause
  2. Patient has AF episodes lasting longer than 7 days
  3. History of heart surgery, or any previous ablation for AF
  4. Myocardial infarction (MI), coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) within preceding 3 months
  5. Documented left atrial thrombus on imaging
  6. (NYHA) class III or IV heart failure
  7. Hypertrophic obstructive cardiomyopathy
  8. Presence of implantable cardioverter defibrillator (ICD)
  9. to isoproterenol
  10. Any other disease or malfunction that would preclude treatment with ablation in the opinion of the investigator
  11. Women who are pregnant and/or breast feeding
  12. Enrollment in an study evaluating another device, biologic, or drug
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
150 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Rate of freedom from documented atrial fibrillation (AF), atrial tachycardia (AT), or atrial flutter (AFL) (≥30 seconds) within 91-365 days post index procedure.

    Atrial tachyarrhythmia recurrence events will be recorded and included as a study endpoint after a 90-day blanking period; recurrence during the blanking will not be considered treatment failure. In addition, re-ablation will not be recommended during the blanking period.

    Time frame: 91-365 days

Secondary outcomes

  1. Rate of acute success at 0.5hour CPVI

    Entrance block rate achieved by all pulmonary veins after 0.5hour waiting time and isoproterenol challenge after CPVI

    Time frame: 91-365 days

  2. Numbers of reconnected pulmonary veins (PV), with number and location of any gaps

    Numbers of pulmonary veins recovered after 0.5hour waiting time and isoproterenol challenge after CPVI, and the location of recovery and number are also recorded

    Time frame: 91-365 days

  3. Mapping time

    Procedural efficiency measures

    Time frame: 91-365 days

  4. Contact force in grams

    Ablation Index values physiological parameter of the Carto 3 which is background data generated during operation

    Time frame: 91-365 days

  5. Rate of adverse events occurred

    Complications related to device or procedure

    Time frame: 91-365 days

  6. Re-hospitalization due to arrhythmia recurrence or procedure-related reasons up to 1 year

    Rate of patients who are back to hospital and got hospitalized due to AF/AT/AFL recurrence or procedure-related reasons during 91 to 365 days after procedure

    Time frame: 91-365 days

  7. Ablation time

    Procedural efficiency measures

    Time frame: 91-365 days

  8. Total procedure time

    Procedural efficiency measures

    Time frame: 91-365 days

  9. Fluid volume delivered via catheter

    Procedural efficiency measures

    Time frame: 91-365 days

  10. Ablation times in seconds

    Ablation Index values physiological parameter of the Carto 3 which is background data generated during operation

    Time frame: 91-365 days

  11. Inter Tag in micrometers

    Ablation Index values physiological parameter of the Carto 3 which is background data generated during operation

    Time frame: 91-365 days

  12. RF ablation and fluoroscopy times in seconds

    Ablation Index values physiological parameter of the Carto 3 which is background data generated during operation

    Time frame: 91-365 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Johnson \& Johnson Medical Device Companies have an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.

Data sharing details ↗ · yoda.yale.edu.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2019 (actual). Primary completion is estimated for Dec 2026, 90 months after the start.

Of 148 industry-sponsored observational studies under Atrial Fibrillation, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's planned 90 months is above that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2019
First posted
May 24, 2019
StartActual
Jun 24, 2019
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date
  2. Sep 28, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03963349
Responsible party
Sponsor
First posted
May 24, 2019
Start date
Jun 24, 2019
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 3, 2026

Study contacts

Shaowen Liu, PhD
principal investigator · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion